<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

RNAseq and FACS Profiling of Syngeneic Mouse Models Treated with Immune Checkpoint Inhibitors enable Biomarker Discovery and Model Selection for Cancer Immunotherapy

 Syngeneic tumor models have long been used in cancer research. Recently, the clinical success of anti-CTLA-4 and anti-PD-1 antibodies has resulted in increased interest in the use of syngeneic models to evaluate cancer immunotherapeutics.